Predictive Factors for Acute and Late Urinary Toxicity After Permanent Prostate Brachytherapy: Long-Term Outcome in 712 Consecutive PatientsMira Keyes, William Morris, Ross Halperin et al.|International Journal of Radiation Oncology*Biology*Physics|2008Cited by 180
Prostate-Specific Antigen at 4 to 5 Years After Low-Dose-Rate Prostate Brachytherapy Is a Strong Predictor of Disease-Free SurvivalAndrea Lo, Ingrid Spadinger, Jeremy Hamm et al.|International Journal of Radiation Oncology*Biology*Physics|2013Cited by 58
Late Urinary Side Effects 10 Years After Low-Dose-Rate Prostate Brachytherapy: Population-Based Results From a Multiphysician Practice Treating With a Standardized Protocol and Uniform Dosimetric GoalsMira Keyes, William Morris, Stacy Miller et al.|International Journal of Radiation Oncology*Biology*Physics|2014Cited by 58
Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: A population-based cohort studyChristopher Herbert, Ingrid Spadinger, Mira Keyes et al.|Radiotherapy and Oncology|2012Cited by 24
Effect of aging and long-term erectile function after iodine-125 prostate brachytherapyMira Keyes, James Morris, Tom Pickles et al.|Brachytherapy|2015Cited by 21